Ex-OpenAI researcher Miles Wang in talks for $2B AI drug discovery startup
What's the deal? OpenAI researcher Miles WangDealroom has a profile for this one. Try Dealroom → is in talks to launch an AI drug discovery startup at a $2 billion valuation, according to reports. Lightspeed Venture Partners is lined up to lead a round of roughly $200 million — a steep price for a company that has yet to launch.
Who's behind it? Wang is an AI researcher and engineer at OpenAI who previously worked at MIT's Computer Science and Artificial Intelligence Laboratory (CSAIL). His stealth venture is developing generative AI models for drug discovery and drug repurposing, including tools to identify new uses for existing and failed medicines.
Why now? Capital and talent are pouring into companies fusing AI with biotech, and a researcher from a frontier AI lab spinning out to found a startup fits a widening pattern of lab talent moving into applied science.
What's the endgame? The startup aims to use AI to accelerate drug discovery — a field where machine learning is increasingly used to identify candidate compounds and shorten development timelines. Repurposing shelved or failed drugs could offer faster, cheaper paths to the clinic than starting from scratch.
What could go wrong? The talks are early, and drug discovery carries long, costly and uncertain paths to market that AI has yet to prove it can reliably shorten. A $2 billion valuation pre-launch leaves little room for error.
The signal: The reported valuation underscores how far investor appetite for AI-in-biotech has run, with backers willing to bet big on unproven ventures led by credentialed AI researchers.
Read more: TechCrunch · The Tech Buzz
